Takeda’s Japan Ethical Sales Sag 6.8% on LLP Transfer, but Underlining Revenue Grows

Takeda Pharmaceutical said on May 10 that it saw its Japan ethical drug sales fall 6.8% year on year to 504.7 billion yen in the year ended March 2017 due to the divestiture of long-listed products (LLPs), or off-patent brand-name...read more